Bioiberica to participate in the 7th Workshop on the Characterization of Heparin Products in London
This is a key meeting in the pharmaceutical industry, in which monographs and heparin quality issues are discussed
Bioiberica focuses on the research, production and sales of this pharmaceutical active ingredient, thus guaranteeing a highly purified and safe product
Bioiberica will attend this week to the workshop jointly organized in London by the National Institute for Biological Standards and Control (NIBSC) and the United States Pharmacopeia (USP).
This event, the largest directed exclusively towards heparin, will center on issues dealing of current international level pharmacopeia monographs and quality attributes of heparin products. The different sessions dealt with various themes: from regulatory norms to characteristics of low molecular weight heparins, among others.
Bioiberica will attend this meeting as a producer of pharmaceutical grade active ingredients, as well as a driving force promoting the research and scientific development of heparin. This biotech firm is a world leader in the production of heparin, and its portfolio of products includes sodium heparin, lithium heparin, ammonium heparin, dermatan sulfate, and heparinoids.
Related News
A crucial initiative to prevent shortages of critical medicines in the European Union.
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.